Methylation of SPINT2 and SRD5A2 + AFP + DCP (sensitivity/specificity): 82.4%/82.1% (training cohort); 73.2%/87.7% (validation cohort)AUC = 0.72 for ≥5 cm HCC and 0.89 for >5 cm HCCAFP alone (sensitivity/specificity): 57.4%/85.7% (training cohort)DCP alone (sensitivity/specificity): 60.2%/89.3% (training cohort). The gene discussed is SPINT2; the disease is hepatocellular carcinoma.